A R Nissenson

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Achieving target hematocrit in dialysis patients: new concepts in iron management
    A R Nissenson
    Department of Medicine, UCLA School of Medicine, USA
    Am J Kidney Dis 30:907-11. 1997
  2. ncbi Optimal hematocrit in patients on dialysis therapy
    A R Nissenson
    Department of Medicine, University of California at Los Angeles, USA
    Am J Kidney Dis 32:S142-6. 1998
  3. ncbi Iron deficiency in patients with renal failure
    A R Nissenson
    Department of Medicine, UCLA School of Medicine, Los Angeles, California, USA
    Kidney Int Suppl 69:S18-21. 1999
  4. ncbi Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization
    A R Nissenson
    University of California at Los Angeles School of Medicine, Los Angeles, CA, USA
    Am J Kidney Dis 37:1177-83. 2001
  5. ncbi Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns
    A R Nissenson
    Department of Medicine, University of California Los Angeles, School of Medicine, Los Angeles, CA 90095, USA
    J Am Soc Nephrol 12:1713-20. 2001
  6. ncbi Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease
    A R Nissenson
    Department of Medicine, and Division of Nephrology, University of California, Los Angeles, School of Medicine, and UCLA Medical Center, Los Angeles, CA 90095, USA
    Am J Kidney Dis 38:1390-7. 2001
  7. ncbi Evaluation of disease-state management of dialysis patients
    A R Nissenson
    University of California at Los Angeles School of Medicine, Los Angeles, CA, USA
    Am J Kidney Dis 37:938-44. 2001
  8. ncbi Erythropoietin and anemia
    E M Tong
    Division of Nephrology, Department of Medicine, UCLA School of Medicine, Los Angeles, CA, USA
    Semin Nephrol 21:190-203. 2001
  9. ncbi The National Anaemia Action Council, Inc.: the primary North American resource for anaemia education and research
    A R Nissenson
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, and The National Anaemia Action Council, Inc, Milwaukee, Wisconsin, USA
    Eur J Clin Invest 35:100-6. 2005
  10. ncbi The new FDA label for erythropoietin treatment: how does it affect hemoglobin target?
    S Fishbane
    Division of Nephrology, Winthrop University Hospital, Mineola, New York 11501, USA
    Kidney Int 72:806-13. 2007

Detail Information

Publications10

  1. ncbi Achieving target hematocrit in dialysis patients: new concepts in iron management
    A R Nissenson
    Department of Medicine, UCLA School of Medicine, USA
    Am J Kidney Dis 30:907-11. 1997
    ....
  2. ncbi Optimal hematocrit in patients on dialysis therapy
    A R Nissenson
    Department of Medicine, University of California at Los Angeles, USA
    Am J Kidney Dis 32:S142-6. 1998
    ....
  3. ncbi Iron deficiency in patients with renal failure
    A R Nissenson
    Department of Medicine, UCLA School of Medicine, Los Angeles, California, USA
    Kidney Int Suppl 69:S18-21. 1999
    ..It is essential, therefore, for renal health professionals to understand iron metabolism in dialysis patients in order to properly balance the therapy of renal anemia with rHuEPO and supplemental iron...
  4. ncbi Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization
    A R Nissenson
    University of California at Los Angeles School of Medicine, Los Angeles, CA, USA
    Am J Kidney Dis 37:1177-83. 2001
    ..The time has come for a structured public and professional educational program to address this serious condition...
  5. ncbi Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns
    A R Nissenson
    Department of Medicine, University of California Los Angeles, School of Medicine, Los Angeles, CA 90095, USA
    J Am Soc Nephrol 12:1713-20. 2001
    ..Providers, policy-makers, and payers should view CKD as a major public health problem and initiate innovative programs to address this growing patient population...
  6. ncbi Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease
    A R Nissenson
    Department of Medicine, and Division of Nephrology, University of California, Los Angeles, School of Medicine, and UCLA Medical Center, Los Angeles, CA 90095, USA
    Am J Kidney Dis 38:1390-7. 2001
    ..There have been no reports of antibody formation associated with NESP. NESP is an important new tool for physicians to use in the treatment of anemia of chronic kidney disease...
  7. ncbi Evaluation of disease-state management of dialysis patients
    A R Nissenson
    University of California at Los Angeles School of Medicine, Los Angeles, CA, USA
    Am J Kidney Dis 37:938-44. 2001
    ....
  8. ncbi Erythropoietin and anemia
    E M Tong
    Division of Nephrology, Department of Medicine, UCLA School of Medicine, Los Angeles, CA, USA
    Semin Nephrol 21:190-203. 2001
    ....
  9. ncbi The National Anaemia Action Council, Inc.: the primary North American resource for anaemia education and research
    A R Nissenson
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, and The National Anaemia Action Council, Inc, Milwaukee, Wisconsin, USA
    Eur J Clin Invest 35:100-6. 2005
    ..This editorial illustrates the goals and objectives of NAAC, and depicts past, present and future educational and research projects and findings. NAAC resources in anaemia-related education and research are described in detail...
  10. ncbi The new FDA label for erythropoietin treatment: how does it affect hemoglobin target?
    S Fishbane
    Division of Nephrology, Winthrop University Hospital, Mineola, New York 11501, USA
    Kidney Int 72:806-13. 2007
    ..In this review, we consider the recent literature, the change in FDA warnings, and new National Kidney Foundation Anemia Guidelines. Suggestions for new Hb targets during erythropoiesis-stimulating agent treatment are presented...